Zafgen (ZFGN) PT Cut to $48 at FBR Capital on Patient Death

Cowen Cuts Price Target on Zafgen (ZFGN) as Beloranib is Placed on Hold Following Patient Death

Cowen reiterated an Outperform rating on Zafgen (NASDAQ: ZFGN), and cut the price target to $20.00 (from $60.00), following FDA'a decision to place beloranib on a partial clinical hold. Late yesterday ZFGN received verbal notice from the FDA that beloranib has been placed on partial... More

Zafgen (ZFGN) PT Lowered to $46 at RBC Capital; Discusses Road Ahead for Beloranib

RBC Capital analyst Simos Simeonidis maintained an Outperform rating and lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 (from $58.00) following a patient death. Simeonidi said while they expect near-term uncertainty, and obviously a very negative outcome is still possible, we see a couple of viable scenarios where none of what has transpired ends up leading to any real negative impact on ZFGN.

The analyst highlighted the following scenarios:

1) The patient death was on the placebo arm (best case scenario: drug's safety profile is "exonerated").... More

RBC Sees 33% of Zafgen (ZFGN) Death Happening in Placebo Arm; Reiterates 'Outperform' Rating

RBC Capital is positive on news from Zafgen (Nasdaq: ZFGN) following news of a death with the company's Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome.

Analyst Simos Simeonidis said the firm spok with Zafgen managmenet and there may be a 33 percent chance that the patient death... More

Leerink Partners Comments on Zafgen (ZFGN) Following Patient Death

Leerink Partners analyst Joseph Schwartz weighed in on Zafgen (NASDAQ: ZFGN) after the company announced a patient death in the ongoing Phase III bestPWS study of beloranib in Prader-Willi Syndrome (PWS).

"This news, while negative, resolves the uncertainty and speculated negativity that... More

Zafgen (ZFGN) Stock Expected to Languish Until More is Known - Cowen

Cowen analyst Phil Nadeau weighed in Zafgen (NASDAQ: ZFGN) announced that a death occurred in its ongoing double-blind, placebo controlled pivotal U.S. Phase III trial of beloranib in Prader-Willi Syndrome.

Nadeau notes the cause of the death is unknown, as was the patient's treatment assignment, thus it is unclear whether the death is drug-related.

The analyst expects the stock to languish until more is known. "Unfortunately, until... More

Zafgen (ZFGN) Worst Case Scenario Avoided, RBC Capital - Bloomberg

Zafgen (NASDAQ: ZFGN) has reversed and moved to the highs of the day following the announcement of a patient death.

RBC analyst said the worst case scenario has been avoided, according to Bloomberg headlines.

Shares are up 10%.

Who Traded Zafgen (ZFGN) on Illegal Insider Information?

After days of speculation and a more 50% drop in its share price, Zafgen (NASDAQ: ZFGN) finally announced what the heck was going on. As expected, the news is not good.

Zafgen said it learned of a patient death in the ongoing Phase 3 bestPWS study of beloranib in Prader-Willi Syndrome, a rare genetic... More

Streetinsider.com's Hot Lunchtime Reads 10/14: (WMT) (ZFGN) (TRIP) (SRPT)

The following is a list of notable articles to help get you through the lunch hour:Others Will Follow Wal-mart (WMT): Bill Gross ->... More

Zafgen (ZFGN) triggers limit-up, limit-down trading pause

Zafgen (NASDAQ: ZFGN) triggers limit-up, limit-down trading pause on resumption.

Zafgen (ZFGN) Learns of Death in Beloranib Phase 3

Zafgen (NASDAQ: ZFGN) is on watch after shares were halted ahead of a news release made early Wednesday afternoon.

In the release, Zafgen... More